Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-12-16
2011-12-27
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S596000, C544S362000, C546S187000, C514S217030, C514S218000, C514S252130
Reexamination Certificate
active
08084466
ABSTRACT:
Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H4receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
REFERENCES:
patent: 7250427 (2007-07-01), Breitenbucher et al.
patent: 7314937 (2008-01-01), Beavers et al.
patent: 2004/0132715 (2004-07-01), Dunford et al.
patent: 2005/0070550 (2005-03-01), Arienti et al.
patent: 2005/0261309 (2005-11-01), Buzard et al.
patent: 2007/0043043 (2007-02-01), Chen et al.
patent: 2007/0232616 (2007-10-01), Edwards et al.
patent: 2007/0244126 (2007-10-01), Edwards et al.
patent: 2007/0265250 (2007-11-01), Buzard et al.
patent: 2008/0267887 (2008-10-01), Yuan et al.
patent: WO 98 31359 (1998-07-01), None
patent: WO 99 18079 (1999-04-01), None
patent: WO 99 65897 (1999-12-01), None
patent: WO 01 00610 (2001-01-01), None
patent: WO 01 47883 (2001-05-01), None
patent: WO 02 00647 (2002-01-01), None
patent: WO 02 20495 (2002-03-01), None
patent: WO 02 076438 (2002-10-01), None
patent: WO 03 000254 (2003-03-01), None
patent: WO 2004 012736 (2004-02-01), None
patent: WO 2004 030625 (2004-04-01), None
patent: WO 2005 032490 (2005-04-01), None
patent: WO 2005 039485 (2005-05-01), None
patent: WO 2005 044807 (2005-05-01), None
patent: WO 2006 102645 (2006-09-01), None
patent: WO 2007 070173 (2007-06-01), None
patent: WO 2007 117399 (2007-10-01), None
patent: WO 2007 120690 (2007-10-01), None
International Search Report dated Feb. 20, 2009 for International Appln. No. PCT/US08/13810.
Robinson et al. “Discovery of the Hemifumarate and (α-L-Alanyloxy)methyl Ester as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group” J Med Chem 1996 vol. 39 pp. 10-18.
Robinson Malcom“Medical Therapy of Inflammatory Bowel Disease for the 21stCentury” Eur J. Surg 1998 Suppl 582 pp. 90-98.
Shan et al. “Prodrug Strategies Based on Intramolecular Cyclization Reactions” Journal of Pharmaceutical Sciences 1997 vol. 86(7) pp. 765-767.
Silverman Richard B. “Prodrugs and Drug Delivery Systems” The Organic Chemistry of Drug Design and Drug Action 1997 Chapter 8 pp. 353-399.
Singh et al. “Immune Therapy in Inflammation Bowel Disease and Models Colitis” British Journal of Surgery 2001 vol. 88 pp. 1558-1569.
Slater et al “Increase in epithelial Mast Cell Numbers in the Nasal Mucosa of Patients with Perennial Allergic Rhinitis” J Laryngol Otol 1996 vol. 110 pp. 929-933.
Steinberg D. “Atherogenesis in Perspective: Hypercholesterolemia and Inflammation as Partners in Crime” Nature Med 2002 vol. 8(11) pp. 1211-1217.
Takeshita et al “Critical Role of Histamine H4Receptor in Leukotriene B4Production and Mast-Cell Dependent Neutrophil Recruitment Induced by Zymosan in Vivo” J Pharmacol Exp Ther 2003 vol. 307(3) pp. 1072-1078.
Terzioglu et al. “Synthesis and Structure-Activity Relationship of Indole and Benzimidazole Piperazines as Histamine H4Receptor Antagonists” Bioorg & Med Chemistry Letters 2004 vol. 14 pp. 5251-5256.
Testa et al “Predicting Drug Metabolism: Concepts and Challenges” Pure Appl Chem 2004 vol. 76(5) pp. 907-914.
Thurmond et al “A Potent and Selective Histamine H4Receptor Antagonist with Anti-Inflammatory Properties” J Pharmacol Exp Ther 2004 vol. 309(1) pp. 404-413.
Tracey K. J. “The Inflammatory Reflex” Nature 2002 vol. 420(6917) pp. 853-859.
Varga et al “Inhibitory Effects of Histamine H4Receptor Antagonists on Experimental Colitis in the Rat” Eur J Pharmacol 2005 vol. 522(1-3) pp. 130-138.
Voehringer et al “Type 2 Immunity Reflects Orchestrated Recruitment of Cells Committed to IL-4 Production” Immunity 2004 vol. 20(3) pp. 267-277.
Weiner et al “Inflammation and Therapeutic Vaccination in CNS Diseases” Nature 2002 vol. 420(6917) pp. 879-884.
Zhichkin et al. “A General Procedure for the Synthesis of 2-Substituted Pyrimidine-5-Carboxylic Esters” Synthesis 2002 vol. 6 pp. 720-722.
Gantner et al. “Histamines H4and H2Receptors Control Histamine-Induced Interleukin-16 Release from Human CD8+T Cells” J Pharmacol Exp 2002 vol. 303(1) pp. 300-307.
Gauvreau et al. “Increased Numbers of Both Airway Basophils and Mast Cells in Sputum after Allergen Inhalation Challenge of Atopic Asthmatics” Am J Resp Crit Care Med 2002 vol. 161(5) pp. 1473-1478.
Gutzmer et al “Histamine H4Receptor Stimulation Suppresses IL-12p70 Production and Mediates Chemotaxis in Human Monocyte-Derived Dendritic Cells” J Immunol 2005 vol. 174(9) pp. 5224-5232.
Hofstra et al. “Histamine H4Receptor Mediates Chemotaxis and Calcium Mobilization of Mast Cells” J Pharmacol Exp Ther 2003 vol. 305(3) pp. 1212-1221.
Ikawa et al. “Histamine H4Receptor Expression in Human Synovial Cells Obtained from Patients Suffering from Rheumatoid Arthristis” Biol Pharm Bull 2005 vol. 28(10) pp. 2016-2018.
Kassel et al “Local Increase in the Number of Mast Cells and Expression of Nerve Growth Factor in the Bronchus of Asthmatic Patients after Repeated Inhalation of Allergen Low-Dose” Clin Exp Allergy 2001 vol. 31(9) pp. 1432-1440.
Kirby et al “Bronchoalveolar Cell Profiles of Asthmatic and NonAsthmatic Subjects” Am Rev Respir 1987 vol. 136(2) pp. 379-383.
Krug et al “Interleukin 16 and T-cell Chemoattractant Activity in Bronchoalveolar Lavage 24 Hours After Allergen Challenge in Asthma” Am J Resp Crit Care Med 2000 vol. 162(1) pp. 105-111.
Libby P. “Inflammation in Atherosclerosis” Nature 2002 vol. 420 pp. 868-874.
Ling et al. “Histamine H4Receptor Mediates Eosiniphil Chemolaxis with Cell Shape Change and Adhesion Molecule Upregulation” Br J. Pharmacol 2004 vol. 104(1) pp. 161-171.
Lippert et al “Human Skin Cells Express H2 and H4, but not H3 Receptors” J Invest Dermatol 2004 vol. 123(1) pp. 116-123.
Liu et al “Cloning of Pharmacological Characterization of a Fourth Histamine Receptor (H4) Expressed in Bone Marro” Mol Pharmacol 2001 vol. 59(3) pp. 420-426.
Mashikian et al “Identification of IL-16 as the Lymphocyte Chemotactic Activity in the Bronchoalveolar Lavage Fluid of Histamine-Challenged Asthmatic Patients” J Allergy Clin Immunol 1998 vol. 101(6 Part 1) pp. 786-792.
Morse et al “Cloning and Characterization of Novel Human Histamine Receptor” J Pharmacol Exp. Ther 2001 vol. 296(3) pp. 1058-1066.
Nathan C. “Points of Control in Inflammation” Nature 2002 vol. 420(6917) pp. 846-852.
O'Reilly et al “Identification of H4Receptor in Human Eosinophilis—Role in Eosinophil Chemotaxis” J Recept Signal Transduction 2002 vol. 22(1-4) pp. 431-448.
Parsons et al. “Histamine and its Receptors” British Jurnal of Pharmacology 2006 vol. 147 pp. S127-S-135.
Amin et al. “Inflammation and Structural Changes in the Airways of Patients with Atopic and NonAtopic Asthma” Am J Respir Crit Care Med 2000 vol. 162(6) pp. 2295-2301.
Bagshawe et al. “Antibody-Directed Enzyme Prodrug Therapy: A Review” Drug Dev Res 1995 vol. 34 pp. 220-230.
Bell et al “Involvement of Histamine H4and H1Receptors in Scratching Induced by Histamine Receptor Agonists in BalbC Mice” Br J Pharmaol 2004 vol. 142(2) pp. 374-380.
Benoist et al “Mast Cells in Autoimmune Disease” Nature 2002 vol. 420(6917) pp. 875-878.
Berge et al. “Pharmaceutical Salts” Journal of Pharmaceutical Sciences 1977 vol. 66(1) pp. 1-19.
Bertolini et al. “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, A Potent Immunosuppressive Drug” J Med Chem 1997 vol. 40 pp. 2011-2016.
Bodor et al. “Novel Approaches to the Des
Kindrachuk David E.
Venable Jennifer D.
Coppins Janet L
Janssen Pharmaceutica NV
Saeed Kamal
LandOfFree
Bicyclic heteroaryl-substituted imidazoles as modulators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic heteroaryl-substituted imidazoles as modulators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic heteroaryl-substituted imidazoles as modulators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4302907